Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration –Time Curve of Imatinib Mesylate in Palestinian Patients with Chronic Myeloid Leukemia
ConclusionThe LSS using one timepoint, especiallyC0, can effectively predict imatinib AUC. This approach offers practical benefits in optimizing dose regimens and improving adherence. However, for more precise estimation of imatinib AUC, utilizing two- or three-timepoint concentrations is recommended over relying on a single point.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Drugs & Pharmacology | Gleevec | Leukemia | Middle East Health | Palestine Health | Study